| COMPASS Pathways is a mental health care company focusing on accelerating patient access to evidence-based innovation in mental health. Co. is developing psilocybin therapy through late-stage clinical trials for patients with treatment-resistant depression. Co. has developed a high-purity polymorphic crystalline formulation of psilocybin, COMP360. COMP360 is Co.'s psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Co.'s investigational COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from trained therapists with specific persibbel and educational qualifications. The CMPS average annual return since 2020 is shown above.
The Average Annual Return on the CMPS average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CMPS average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CMPS average annual return calculation with any dividends reinvested as applicable (on ex-dates).